Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Annexon Biosciences ( (ANNX) ) is now available.
On January 14, 2026, Annexon updated its corporate presentation ahead of the 44th Annual J.P. Morgan Healthcare Conference, highlighting 2026 as a pivotal year driven by multiple late-stage assets in neuroinflammatory diseases and reinforcing its positioning around C1q inhibition as a differentiated therapeutic platform. The company underscored blockbuster potential for vonaprument, in a Phase 3 registrational trial for dry age-related macular degeneration with geographic atrophy, and tanruprubart for Guillain-Barré syndrome, alongside a diversified pipeline and sufficient cash runway into late 2027, signaling an intensifying push toward regulatory submissions, potential commercialization, and value creation in markets with limited or no effective treatments.
The most recent analyst rating on (ANNX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Annexon Biosciences stock, see the ANNX Stock Forecast page.
Spark’s Take on ANNX Stock
According to Spark, TipRanks’ AI Analyst, ANNX is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, widening losses, and accelerating cash burn with likely future funding needs). Offsetting factors include constructive technical momentum and supportive corporate developments, including financing and defined 2026 clinical/regulatory milestones, while valuation signals are limited due to negative earnings and no dividend.
To see Spark’s full report on ANNX stock, click here.
More about Annexon Biosciences
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing complement-based immunotherapies that inhibit the C1q component of the classical complement cascade to halt neuroinflammation at its source. Its late-stage pipeline targets neuroinflammatory diseases with high unmet need, notably dry age-related macular degeneration with geographic atrophy and Guillain-Barré syndrome, and includes both antibody therapies such as vonaprument and tanruprubart and a first oral C1 inhibitor, with a strategic emphasis on large, underserved markets in ophthalmology and autoimmune neurology.
Average Trading Volume: 2,768,712
Technical Sentiment Signal: Buy
Current Market Cap: $804.7M
See more data about ANNX stock on TipRanks’ Stock Analysis page.